Abstract: Availability of a single source review of once-daily fixeddose single tablet regimen (STR) and multiple tablet fixed-dose regimen (MTR) would optimally inform healthcare providers and policy makers involved in the management of population with human immunodeficiency virus (HIV).
INTRODUCTION

I
n 2013, there were approximately 35 million people living with and 1.5 million people dying from human immunodeficiency virus (HIV) worldwide. 1 About 12.9 million people living with HIV were receiving antiretroviral therapy (ART) globally, including 11.7 million in low-and middle-income countries. 1 ART is recommended by the World Health Organization (WHO) as an effective treatment for HIV disease progression and prevention. 1 Both the Joint United Nations Programme on HIV and AIDS (UNAIDS) and WHO recommend initiating combination antiretroviral therapy (cART) containing a ''backbone'' of 2 nucleoside reverse transcriptase inhibitors along with a ''base'' consisting of either a nonnucleoside reverse transcriptase inhibitor, a ''boosted'' protease inhibitor, or an integrase inhibitor. 2 Medical providers continually seek regimen simplification to help achieve and maintain HIV treatment adherence. Fixeddose combination (FDC) ART medications combine elements of backbone and base medications into fewer dosing units and offer simplified regimen options to HIV patients. Single tablet regimens (STR) incorporate FDC into a single dosing unit that is administered once daily; multiple tablet regimens (MTR) incorporate FDC and require multiple dosing times or units per day. Regardless of disease being treated, adherence rates tend to be higher when simpler, once-daily regimens are combined with lower pill burden. [3] [4] [5] [6] [7] [8] Studies have suggested that HIV patients treated with once-daily fixed-dose STR are more adherent compared to patients on !2 pills per day regimens, [9] [10] [11] [12] and that patients on STR were better at achieving >90% adherence when compared with MTR. 13, 14 Therefore, several guidelines urge providers to use STR and MTR containing FDCs when choosing regimens of similar efficacy and tolerability for their patients. 2, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] STRs may provide long-term durability, allowing for continued immunological recovery, leading to increased life expectancy. 26 -27 Further, STRs appear to generate improved adherence, higher perceived quality of life (QoL), and lower costs to the healthcare system. 3,10,28 -31 To confirm these hypotheses, formal investigation is required. At present, there are no literature reviews or meta-analyses comparing STR to MTR using randomized controlled trials (RCT), observational studies (OS), and economic models (EM) encompassing patient adherence, clinical outcomes, and economic outcomes. Availability of a single-source review of single-tablet compared with multi-tablet HIV regimens containing FDCs would optimally inform healthcare providers and policy makers involved in the management of HIV populations amidst increasingly scarce resources.
METHODS
Search Strategy and Study Selection
A literature review and meta-analysis of published scientific articles, focusing on STR compared with MTR for the management of HIV was completed employing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 32 and ''PICOS principle'' (Patient, Intervention, Comparator, Outcome, and Study design) based on an internal study protocol (available upon request). Research followed a 2-level screening process conducted independently by 2 reviewers. Databases were searched from November to December 2014 and included Embase, PubMed (Medline inprocess), and ClinicalTrials.gov. Articles published in English, beginning in 2005, when STR Atripla was first introduced, to December 2014 were considered for the analyses. The search criteria used in this research is depicted in the Supplemental Content accompanying this manuscript, http://links.lww.com/ MD/A444. Data sought included published or publicly available RCT and observational study results on human subjects which included: patient adherence, clinical efficacy, safety, resource utilization, and cost outcomes. The methodological quality of RCT was assessed independently using a checklist that assessed the risk of bias across 5 different categories (selection, performance, detection, reporting, and attrition), according to the Cochrane handbook for systematic reviews. 33 A critical appraisal was conducted for the OS included in the meta-analysis, using the Critical Appraisal Skills Programme (CASP), United Kingdom checklist, 34 assessing the validity of the results from each study. The first-pass screening of bibliographic details, titles, and abstracts of all citations retrieved by the literature search eliminated citation duplicates. Studies found eligible and presenting relevant data were included for data extraction. Only studies with outcome measures in evaluable format (n/N, mean, standard deviation, N, or median and inter-quartile range) with a clear comparison between STR and MTR were included for meta-analysis. Because only secondary/published literature was considered for this research and no human subjects were approached or included in this research in any manner, an internal peer review process was adopted for review of the study documents; an external independent institutional review board (IRB) approval was not considered necessary.
Meta-Analysis
A random-effects meta-analysis with forest plots was carried out to investigate the parameters of interest from the included studies using Review Manager (RevMan 5.1.7) software (The Nordic Cochrane Centre, Copenhagen, Denmark). The primary endpoints were reported for adherence outcomes based on either achieving a specific threshold measure (yes/no) or based on pill count or percentage of drugs used; efficacy outcomes based on either percentage achieving viral load suppression (<50 copies/mL) at 48 weeks or changes in mean CD4 counts from baseline at 48 weeks; safety outcomes based on percentage having any severe adverse event (SAE) at 48 weeks, any grade 3 to 4 clinically significant event at 48 weeks, or any grade 3 to 4 lab abnormalities at 48 weeks; and tolerability outcomes based on the percentage of patients discontinuing their STR or MTR HIV treatment for any reason. The adherence outcomes were also assessed based on the frequency of MTR regimen (subject to data availability), as prespecified in the study protocol. The qualifying economic studies are not included in the meta-analyses since the data were not in an analyzable format. The studies are retained and summarized in the review; however, in keeping with 1 of the study objectives (provide a single-source review of STR compared with MTR for HIV to inform healthcare providers and policy makers amidst increasingly scarce resources).
Inverse variance methods were used in a random-effects model to analyze both dichotomous and continuous data and to assess heterogeneity. 35 Heterogeneity was evaluated using the Chi-squared test and quantified using the I 2 statistic. 36 Alpha < 0.05 was used to determine statistical significance. I 2 values of 25%, 50%, and 75% correspond to low, medium, and high levels of heterogeneity, respectively. Summary statistics were calculated for each study to describe observed treatment effects; mean and standard deviation values were calculated where studies reported median and inter-quartile range. A pooled treatment effect estimate was then calculated as the weighted average of the treatment effects estimated in the individual studies. Each study was weighted as the inverse of the variance of the effect estimate (ie, 1 over the square of its standard error). Larger studies with smaller standard errors were given more weight than smaller studies with larger standard errors. For the studies which had multiple MTR arms, data from the MTR arms were first pooled within the trials and then between the trials. Dichotomous outcomes were evaluated by making an adjustment to the study weights according to the extent of variation, or heterogeneity, among the treatment effects. Values for dichotomous outcomes (adherence [based on a threshold measure; yes/no], viral load suppression, safety events, and tolerability) were presented as n/N, where n ¼ subset of sample size; N ¼ total sample size, and the odds ratio (OR) or risk ratio (RR) with 95% confidence intervals (CI) were calculated. Values for continuous outcomes (CD4 cell counts and adherence [based on pill count or percentage of drug(s) used]) were presented as mean, standard deviation (SD), and N (sample size), with calculated standardized mean differences. For economic evaluations where studies reported healthcare resource use (HRU), the direct medical costs and Incremental CostEffectiveness Ratio (ICER) values were summarized.
RESULTS
Literature searches from all databases yielded 3681 citations, of which 158 were duplicates and discarded, resulting in 3523 unique citations. Following the first review of the abstracts, 165 potentially relevant studies were identified. Two additional relevant studies were identified from hand searching of bibliographies. Thereafter, following a detailed examination of the 167 full-text articles, 124 articles did not meet the inclusion criteria and 8 were identified as secondary publications, thus linked to the primary publications. Consequently, a total of 35 studies 9-11,13 -14,27,29 -31,37-62 were included for qualitative evidence synthesis. The PRISMA flow of the review process is shown in Figure 1 .
Of the 35 publications, 18 were OS (which included prospective and retrospective designs covering adherence, clinical and health resource use/cost-effectiveness outcomes), 9 -11,13-14,30-31,42 -48,54,58 -60 13 were RCT, 27,38-39,41,49,50,51-53,55 -57,62 and 4 were EM-based studies. 29, 37, 40, 61 Twenty-four studies reported efficacy outcomes, 20 reported adherence outcomes, 16 had measured safety/tolerability outcomes, 6 focused on economic evaluations, 4 were EM-based studies, and 1 reported treatment persistence. Seventeen studies (RCT: 9, OS: 6, and EM: 2) included only treatment-naïve patients, 9 (RCT: 4 and OS: 5) included only treatment-experienced patients, and 9 (OS: 7 and EM: 2) included both treatment-experienced and treatment-naive patients. Most studies were from the years 2014 (n ¼ Table 1 . Of these studies, only 9 studies were found eligible for metaanalyses, as they had outcome measures in evaluable format (n/N, mean, standard deviation, N, or median and inter-quartile Table 2 . For the 9 studies included in the meta-analyses, RCT were assessed for quality measures per the Cochrane handbook for systematic reviews and OS were assessed using the CASP checklist. For the RCT, a low risk of bias was observed, with unclear observations for blinding in treatment allocations; for OS, 2 were rated as medium and 3 as satisfactory. The detailed assessments are presented in Table 3A (Fig. 2B) .
Efficacy Outcomes
Twenty-four of the 35 studies reported efficacy data for viral load suppression and CD4 count. After excluding studies that reported data time points other than 48 weeks and/or parameters not in a quantifiable format, 3 studies 38,41,53 provided analyzable data for viral load suppression (<50 copies/ mL) at 48 weeks comparing STR to MTR and the same 3 studies 38, 41, 53 reported change in CD4 cell count at 48 weeks for the analysis. The viral load suppression at 48 weeks was found to significantly better for STR cohorts in comparison to MTR cohorts (RR: 1.09 [95% CI: 1.04-1.15], P ¼ 0.0003); no heterogeneity between the studies were observed (Fig. 3A) . The standardized mean difference in CD4 cell count between STR and MTR was not statistically significant at 48 weeks (SMD: À0.01 [95% CI: À0.14 to 0.11], P ¼ 0.83), and no heterogeneity between the studies was observed (Fig. 3B) . Meta-analyses of SAEs, grade 3 to 4 AEs and mortality revealed no statistically significant differences between STR and MTR (Fig. 3C) (Fig. 3D) . High heterogeneity was observed in the tolerability studies (chi 2 ¼ 8.63, i 2 ¼ 65%), potentially due to variation in study design/population.
Economic Summary
Ten economic studies were critically evaluated (6 economic evaluations [10] [11] [30] [31] 44 ,47 and 4 model-based studies), 29, 37, 40, 61 but none were included in the meta-analysis. In terms of HRU, 1 study 10 reported lower inpatient and outpatient services, number of prescriptions, and total healthcare encounters per month for patients on STR in comparison with 2 or more pills per day. Similarly, a second 31 reported substantially lower inpatient service use among both non-AIDS and AIDS patients on STR versus those on MTR and other regimens while also finding comparable costs/patient/year at 6 and 12 months. A third 47 study reported marginally, but not statistically significantly, lower total cost per day for the FDC regimen (including STR) compared with the other regimen. A fourth 44 reported insignificantly lower average wholesale prices for STR (vs MTR). Two studies 30, 63 reported statistically significantly lower total HRU costs per month (P ¼ 0.0001) and lower mean annual cost (P ¼ 0.0001) in STR patients compared with MTR. The only available mathematical model-based studies offer conflicting outcomes in that 1 reported higher annual cost/person and higher ICER for branded STR in comparison to generic alternatives 61 whereas a second reported statistically significantly lower annual cost associated with STR (P ¼ 0.0001), 40 both comparing to MTR. The sixth 37 reported only marginal cost savings associated with switching from any cART to STR; this study also projected annual average HRU-related cost decreases of 0.6% to 6.1% and 0.9% to 8.6% for overall HRU-related costs and ART treatment only, respectively, when considering impact of ART generics in the 2012 to 2016 time period. 37 Lastly, 1 study found STR to be the most cost-effective owing to higher quality-adjusted life-years (QALYs) and the corresponding lower ICER compared with MTR. 29 
DISCUSSION
This meta-analysis found 1 of the efficacy outcomes (change in CD4 cell count at 48 weeks), tolerability (discontinuation due to any reason), and select safety outcomes (any SAEs, grade 3 to 4 AEs and mortality) to be comparable between STR and MTR. The incidence of Grade 3 to 4 laboratory abnormalities was found to be statistically significantly lower in the STR group (P ¼ 0.02) while the viral load suppression (at 48 weeks) was found to be statistically significantly higher in the STR group (P ¼ 0.0003), in comparison to the MTR group. An additional body of evidence identified in the qualitative evidence synthesis further depicted STR to have impact on maintaining virologic and immunologic efficacy and was found to be generally tolerable with lower AEs, while resulting in better adherence, in comparison to MTR. 13, 27, 45, 58, 64 Collectively, these data portray STR as durable once initiated without sacrificing treatment goals. Theoretically, as STR prohibits splitting of agents into individual components, providers' assurance is heightened that patients are receiving the correct dose of all prescribed medications.
Another important finding in this meta-analysis is the confirmation of adherence-related benefits associated with STR. The odds of adherence associated with STR was found to be 2.37 times higher than MTR (P < 0.0001), and the odds remained in favor of STR irrespective of whether MTR was administered once (P ¼ 0.01) or twice daily (P ¼ 0.02). Further, STR resulted in statistically significant higher medication adherence using ''pill count'' (P < 0.0001). This aligns with historical meta-analyses 7, 8 and reinforces observations 48 of patients on STR to be 2.1 times more likely to have complete antiretroviral adherence.
ART adherence is critical to not only better health but also to improved QoL, HIV prevention, HIV viral load suppression, drug resistance prevention, and ultimately survival. 3, 7, 10, 15, 27, [65] [66] [67] [68] [69] [70] Highly associated with failure to adhere are unfavorable health outcomes beyond HIV such as cardiovascular and cerebrovascular disease, 4,71-73 auto-immune disease, 5 and mental illness. 74 It is established that there are statistically significant effects of reduction in pill burden on improving adherence correlated to improved patient QoL when switched from individual components to an STR. 13 Economically supporting the clinical findings, STR lowered resource utilization in comparison to patients on MTR. 10, 31 Mean costs (annual, bi-annual, monthly, or perdiem) were found to be lower for the STR group compared with multiple tablets 30, 40, 44, 47, 63 and deemed cost-effective as a function of lower ICER. 29 These observations may have important implications for patients and their healthcare systems. Currently, several national and regional payers across the world are exercising fiscal management of healthcare expenditures, putting pressure on healthcare providers to adhere to standard clinical treatment guidelines and to document evidence for improved health outcomes and resource savings, which supports continued reimbursement of costly medicines. [75] [76] [77] Since HIV is managed as a chronic disease, demonstrated savings in HRU and associated costs may help healthcare systems to spare resources to expand the safety net for the HIV population in need of care. This effect is even more pronounced in resource-poor settings, where the stakeholders are sometimes forced to make choices between treatment efficacy/safety and cost. Both policymakers and providers are focused on the rapid scale-up of affordable and effective healthcare interventions to provide timely access to care and to further reduce the spread of HIV. 3,15,28,78 -79 The WHO has advised countries to consider in-country cART costs and has encouraged implementation of public health approaches to scaling up quality HIV care and treatment and 69,77,80 -82 In such scenarios, access to STR may prove valuable for patients, physicians, and healthcare systems over the long term. Recent updates on guidelines from WHO, UNAIDS, and various countries support the use of FDC regimens, and many particularly mention STR as 1 of the primary recommended treatments in the management of HIV across the world. 2,15 -25,83 Widespread use of ARTs (including STRs) may initially increase the ART-specific budget for resource-limited settings, but could also lower overall HRU in the long-term and facilitate achievement of public health goals. 84, 85 
STUDY STRENGTHS AND LIMITATIONS
The strengths of this review include a search strategy with explicit inclusion and exclusion criteria and the use of a random-effects model to assess pooled estimates extracted from RCT and OS, minimizing the risk of outliers in the accompanying heterogeneity analyses. Since the focus of this analysis was to specifically compare FDC-containing STR to MTR, a large number of studies were excluded on the basis of analyzable data with accurate and quantifiable measurement of outcomes of interest. Efficacy results were reported at several time-points across the included studies; however, only 48-week outcomes data were included in the analyses for consistency. Variations in the patient population characteristics at baseline were also noted and assumed to contribute to heterogeneity in the analytic results in some instances. Finally, dosing scheme may just be 1 of the differences between the regimens when examining these particular health and economic outcomes.
CONCLUSIONS
The findings from this literature review and meta-analysis depicted comparable tolerability, safety (all SAE and Grade 3-4 AE), mortality results and changes in CD4 cell counts between patients on FDC-containing STR and MTR. However, patients on STR have statistically significantly better viral load suppression (<50 copes/mL), fewer Grade 3 to 4 lab abnormalities and better adherence compared with patients on MTRall critical to long-term ART goals. 15, 27, 66, 67 Additionally, these analyses discovered potentially reduced treatment and HRU and costs in patients taking STR in comparison to MTR. To the best of our knowledge, this study represents the most upto-date and comprehensive evidence on FDC-containing STR versus MTR, encompassing both clinical and economic outcomes.
